Memorial Sloan Kettering Cancer Center

QBiotics reported an 80% objective response rate in Stage 1 of its Phase IIa trial evaluating tigilanol tiglate in 10 patients with advanced soft tissue sarcoma.

Lisocabtagene maraleucel (liso-cel) demonstrated a 95.5% overall response rate and 62.1% complete response rate in 66 patients with relapsed/refractory marginal zone lymphoma in the TRANSCEND FL trial.

Curadev Pharma and Memorial Sloan Kettering Cancer Center are expanding their collaboration through MSK's Therapeutics Accelerator program to advance development of CRD3874-SI, a first-in-class allosteric STING agonist.

ImPact Biotech's first patient in a Phase 1 trial of Padeliporfin VTP therapy for locally advanced pancreatic ductal adenocarcinoma successfully underwent surgical resection after being initially deemed inoperable.

Minerva Biotechnologies published research demonstrating that MUC1*-targeted CAR-T cells with 1XX mutations show increased persistence and ability to kill low antigen-expressing cancer cells in animal models.

Juri Biosciences, a TCG Labs Soleil portfolio company, has entered into a worldwide licensing agreement with EpimAb Biotherapeutics for exclusive global rights to a KLK2-targeted T-cell engager for metastatic prostate cancer treatment.

Pharmacists have evolved from traditional dispensing roles to comprehensive patient management in cancer care, particularly with novel therapies like CAR-T cell therapy and bispecific antibodies.

Research led by Dr. David Abramson reveals that Coats' disease, traditionally considered unilateral, shows bilateral involvement when examined with fluorescein angiography, challenging long-held clinical beliefs.

Conventional chemotherapy remains essential for advanced epithelioid sarcoma treatment, with ifosfamide and gemcitabine combinations preferred for aggressive disease or patients unsuitable for localized therapies.

• Actinium Pharmaceuticals has enrolled the first patient in a pioneering trial evaluating Iomab-ACT as a targeted radiotherapy conditioning agent with commercial CAR-T therapy, with initial data expected in late 2025. • Iomab-ACT targets CD45 on immune cells and has shown promise in reducing serious CAR-T toxicities including ICANS and CRS, potentially addressing major barriers to CAR-T therapy access and efficacy. • The therapy could significantly expand the $4 billion CAR-T market by replacing conventional chemotherapy conditioning regimens, potentially benefiting approximately 150,000 patients diagnosed annually with eligible conditions.